Physician profile
Ananta Subedi
NPI 1467737601
$3,956.82
in general payments reported to CMS, 2019-2025
23 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $238 · 2021: $189 · 2022: $57.44 · 2023: $1,973 · 2024: $206 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,840 · Food and Beverage: $1,238 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,840.00 |
| Food and Beverage | $1,237.88 |
| Education | $128.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,924.35 | 2020-2023 | Cimzia |
| Amgen INC. | $357.01 | 2020-2025 | Krystexxa, Otezla, Uplizna |
| Janssen Biotech, INC. | $277.79 | 2019-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $140.62 | 2019-2025 | |
| Genzyme Corporation | $138.51 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $128.14 | 2024 | Saphnelo |
| Aurinia Pharma U.S., INC. | $125.08 | 2021 | |
| Glaxosmithkline, LLC. | $120.82 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $81.61 | 2019-2023 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $77.08 | 2019-2025 | Orencia |
| Pfizer INC. | $73.22 | 2019-2022 | |
| Horizon Therapeutics Plc | $72.14 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.87 | 2019-2021 | |
| Abbott Laboratories | $67.27 | 2025 | Eterna |
| Novartis Pharmaceuticals Corporation | $62.97 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $60.11 | 2022-2025 | Opsumit, Uptravi |
| Alexion Pharmaceuticals, INC. | $47.49 | 2025 | Strensiq |
| Regeneron Healthcare Solutions, INC. | $33.68 | 2019 | |
| Sonex Health, INC. | $23.68 | 2025 | Sx-One Microknife |
| Medtronic, INC. | $23.11 | 2023 | Intellis Adaptivestim |
| Genentech USA, INC. | $23.04 | 2019 | |
| Ani Pharmaceuticals, INC. | $17.16 | 2025 | Purified Cortrophin Gel |
| Mylan Institutional INC. | $13.07 | 2023 | Hulio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ananta Subedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.